Skip to main content
Premium Trial:

Request an Annual Quote

Rainbow Genomics, UCLA Partner to Offer Exome Dx in Asia

NEW YORK (GenomeWeb) – Rainbow Genomics, a Hong Kong-based genetic testing company, said today that it plans to contract data analysis and clinical interpretation from the University of California, Los Angeles Clinical Genomics Center for its exome-sequencing tests.

Rainbow's exome sequencing tests cover cardiovascular diseases as well as both adult and pediatric genetic disorders. The firm noted that it also covers Asian-specific genes that are not often included in many panel-based gene tests.

Under the alliance, sequencing will be performed at Rainbow's CAP-accredited laboratory, while the UCLA Clinical Genomics Center will deliver clinical reports.

Daniel Siu, CEO of Rainbow Genomics, said in a statement that the relationship between Rainbow and UCLA will enable "many middle-class families to access exceptionally high-quality exome sequencing genetic tests that may finally provide a diagnosis."

Wayne Grody, director of molecular diagnostics at the UCLA Health System, added that Asian countries, despite their "robust economies and impressive technology," have "remained underserved in the areas of genetic testing and genomic medicine."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.